Authors: BONNY, C.¹; FONTAINE, H.²; POYNARD, T.³; HÉZODE, C.⁴; LARREY, D.⁵; MARCELLIN, P.⁶; BOURLIÈRE, M.⁷; BRONOWICKI, J. P.⁸; MERLE, P.⁹; ZARSKI, J. P.¹⁰; SAPEY, T.¹¹; GUILLEMARD, C.¹²; UGHETTO, S.¹³; HENQUELL, C.¹⁴; NICOLAS, C.¹; ROCHE, C.¹; RANDL, K.¹; BOMMELAER, G.¹; ABERGEL, A.¹

Source: Alimentary Pharmacology & Therapeutics, Volume 24, Number 4, August 2006 , pp. 593-600(8)

Publisher: Wiley-Blackwell

Abstract:

Summary Aim

To assess the rate of sustained virological response in naïve hepatitis C virus-type 5 patients treated by standard interferon or percutaneous endoscopic gastrostomy-interferon (peg-interferon) and ribavirin combination for 48 weeks. Patients and methods

A total of 87 hepatitis C virus patients were included from 12 centres in France; 28 patients received interferon plus ribavirin and 59 were treated with peg-interferon plus ribavirin. Results

Baseline characteristics were: mean age 58 ± 11 years, sex ratio 1, 66% had metavir fibrosis score ≥F2, 21% were cirrhotics and 53% had pretherapeutic viral load ≥800 000 IU/mL. Sustained virological response was achieved in 64% and 58% of hepatitis C virus-5 patients treated with interferon and peg-interferon, respectively (NS). In adherent patients, sustained virological response was obtained in 75% of patients. Sustained virological response in hepatitis C virus-5 patients (60%) was significantly higher than sustained virological response in hepatitis C virus-1 patients (37%) (P = 0.0499) and not significantly different from sustained virological response in hepatitis C virus-2-3 patients (63%) (P = 0.8098). Conclusions

Combination therapy is effective in 60% of hepatitis C virus-5-infected patients. Sustained virological response seems better in hepatitis C virus-5 patients than in hepatitis C virus-1 patients, and is similar to that of hepatitis C virus-2-3 patients. More studies are needed to determine optimal duration of treatment in hepatitis C virus-5 patients.

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1365-2036.2006.03018.x

Affiliations: 1: Service d'Hépato-Gastroentérologie, Hôtel-Dieu, Clermont-Ferrand 2: Service d'Hépatologie, Hôpital Necker 3: Service d'Hépato-Gastroentérologie, Hôpital La Pitié Salpetrière, Paris 4: Service d'Hépatologie, Hôpital Henri Mondor, Créteil 5: Service d'Hépato-Gastroentérologie, CHU de Montpellier 6: Service d'Hépato-Gastroentérologie, Hôpital Beaujon, Paris 7: Service d'Hépato-Gastroentérologie, Hôpital Saint-Joseph, Marseille 8: Service d'Hépato-Gastroentérologie, CHU de Nancy 9: Service d'Hépato-Gastroentérologie, Hôpital Edouard Herriot, Lyon 10: Service d'Hépato-Gastroentérologie, CHU de Grenoble 11: Service d'Hépato-Gastroentérologie, CHR de Châteauroux 12: Service d'Hépato-Gastroentérologie, CHU de Caen 13: Service d'Epidémiologie, Hôtel-Dieu, Clermont-Ferrand 14: Service de Virologie, Faculté de Médecine, Clermont-Ferrand, France

Publication date: 2006-08-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Pathology ,  Pharmacology ,  Surgery ,  Therapeutics & Alternative Medicine
• By this author: BONNY, C. ;  FONTAINE, H. ;  POYNARD, T. ;  HÉZODE, C. ;  LARREY, D. ;  MARCELLIN, P. ;  BOURLIÈRE, M. ;  BRONOWICKI, J. P. ;  MERLE, P. ;  ZARSKI, J. P. ;  SAPEY, T. ;  GUILLEMARD, C. ;  UGHETTO, S. ;  HENQUELL, C. ;  NICOLAS, C. ;  ROCHE, C. ;  RANDL, K. ;  BOMMELAER, G. ;  ABERGEL, A.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers